Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363042 | 1.00 | DNMT3B (0.71) | DNMT3BDNMT1ADORA3ADORA2ADOT1L | |
| SCHEMBL5356383 | 0.90 | ADORA3 (0.78) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL5356397 | 0.90 | ADORA3 (0.78) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL13860338 | 0.86 | ADORA3 (0.77) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL5354351 | 0.86 | ADORA3 (0.77) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL13860337 | 0.86 | ADORA3 (0.77) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL5354361 | 0.86 | ADORA3 (0.77) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL18176248 | 0.86 | ADORA3 (0.77) | DNMT3BDNMT1ADORA3ADORA2ACA1 | |
| SCHEMBL6897966 | 0.85 | DOT1L (0.83) | DNMT3BDNMT1DOT1LPRMT7 | |
| SCHEMBL30216716 | 0.85 | DOT1L (0.83) | DNMT3BDNMT1DOT1LPRMT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | claimed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | claimed |
| US-7189706-B2 | C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2007-03-13 | — | — | US | disclosed |
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | UNIVERSITEIT LEIDEN (NL) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127452-A1 | C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them | ADORA2A, ADORA3, ADORA1 | DNMT3B 3784/4885DNMT1 2984/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.